US 12,728,105 B2
Compounds for the treatment of bacterial infections and potentiation of antibiotics
Binghe Wang, Marietta, GA (US); David W. Boykin, Atlanta, GA (US); Arvind Kumar, Lilburn, GA (US); Mengyuan Zhu, Cary, NC (US); Manjusha Roy Choudhury, Atlanta, GA (US); and Bingchen Yu, Atlanta, GA (US)
Assigned to GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC., Atlanta, GA (US)
Appl. No. 17/757,644
Filed by GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC., Atlanta, GA (US)
PCT Filed Dec. 18, 2020, PCT No. PCT/US2020/066036
§ 371(c)(1), (2) Date Jun. 17, 2022,
PCT Pub. No. WO2021/127452, PCT Pub. Date Jun. 24, 2021.
Claims priority of provisional application 62/950,852, filed on Dec. 19, 2019.
Prior Publication US 2023/0105108 A1, Apr. 6, 2023
Int. Cl. C07D 307/36 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/165 (2006.01); A61K 31/277 (2006.01); A61K 31/33 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/407 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/43 (2006.01); A61K 31/431 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/44 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/5383 (2006.01); A61K 31/55 (2006.01); A61K 31/575 (2006.01); A61K 31/65 (2006.01); A61K 31/702 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7052 (2006.01); A61K 31/7056 (2006.01); A61K 38/12 (2006.01); A61P 31/04 (2006.01); C07C 219/28 (2006.01); C07C 257/18 (2006.01); C07C 279/18 (2006.01); C07C 323/45 (2006.01); C07D 213/30 (2006.01); C07D 233/20 (2006.01); C07D 233/22 (2006.01); C07D 235/18 (2006.01); C07D 239/06 (2006.01); C07D 307/52 (2006.01); C07D 307/54 (2006.01); C07D 307/68 (2006.01); C07D 333/20 (2006.01); C07D 333/22 (2006.01); C07D 345/00 (2006.01); C07D 403/04 (2006.01); C07D 405/04 (2006.01); C07D 409/04 (2006.01); C07D 409/14 (2006.01)
CPC A61K 31/155 (2013.01) [A61K 31/137 (2013.01); A61K 31/165 (2013.01); A61K 31/277 (2013.01); A61K 31/33 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/407 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/43 (2013.01); A61K 31/431 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5383 (2013.01); A61K 31/55 (2013.01); A61K 31/575 (2013.01); A61K 31/65 (2013.01); A61K 31/702 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7052 (2013.01); A61K 31/7056 (2013.01); A61K 38/12 (2013.01); A61P 31/04 (2018.01); C07C 219/28 (2013.01); C07C 257/18 (2013.01); C07C 279/18 (2013.01); C07C 323/45 (2013.01); C07D 213/30 (2013.01); C07D 233/20 (2013.01); C07D 233/22 (2013.01); C07D 235/18 (2013.01); C07D 239/06 (2013.01); C07D 307/52 (2013.01); C07D 307/54 (2013.01); C07D 307/68 (2013.01); C07D 333/20 (2013.01); C07D 333/22 (2013.01); C07D 345/00 (2013.01); C07D 403/04 (2013.01); C07D 405/04 (2013.01); C07D 409/04 (2013.01); C07D 409/14 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising a compound of Formula VI:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibacterial antibiotic for treating a bacterial infection in a host in need thereof wherein:
R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, —COOR, —C(O)R, fluorine, chlorine, bromine, and iodine
R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, —NHSO2alkyl, —N(alkyl) SO2alkyl, —NHSO2aryl, —N(alkyl)SO2aryl, —NHSO2alkenyl, —N(alkyl)SO2alkenyl, —NHSO2alkynyl, —N(alkyl)SO2alkynyl, NO2, —COOH, —CONH2, —P(O)(OH)2, —S(O)R3, —SO2R3, —SO3R3, —SO2N(R3)2, —OSO2R3, —N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and
R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, —NHSO2alkyl, —N(alkyl)SO2alkyl, —NHSO2aryl, —N(alkyl)SO2aryl, —NHSO2alkenyl, —N(alkyl)SO2alkenyl, —NHSO2alkynyl, —N(alkyl)SO2alkynyl, NO2, —COOH, —CONH2, —C(O)R, —P(O)(OH)2, —S(O)R3, —SO2R3, —SO3R3, —SO2N(R3)2, —OSO2R3, —N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano;
wherein at least one of R10 or R11 is not fluorine.